12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ferinject: Phase III data

The 56-week, open-label, international Phase III FIND-CKD trial in >600 non-dialysis dependent CKD patients with iron deficiency anemia showed that IV Ferinject met the primary endpoint of increasing the time to initiation of other anemia management such as erythropoietin stimulating agents (ESAs) or blood transfusions vs. oral iron. Patients received IV Ferinject at a...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >